Spotlight on AbbVie: Analyzing the Surge in Options Activity
AbbVie is a pharmaceutical firm with a strong exposure to immunology (with Humira, Skyrizi, and Rinvoq) and oncology (with ...
AbbVie: CHMP Adopts Positive Opinion For Mirvetuximab Soravtansine - Quick Facts
AbbVie (ABBV) announced the European Medicines Agency's Committee for Medicinal Products for Human Use has adopted a positive opinion ...
AbbVie Gets CHMP Backing for Elahere in Ovarian Cancer
Elahere, which won initial U.S. Food and Drug Administration approval in 2022 for platinum-resistant ovarian cancer, was the key asset in AbbVie's $10.1 billion acquisition of biotech ImmunoGen that ...
Taiwan News2d
Autoinjectors Market Expected to Reach USD 9.73 Billion by 2030, Growing at 18.5% CAGR
The global autoinjectors market size was estimated at US$ 1,505.0 million in 2019. The global autoinjectors market is expected to reach $ 9,732.6 million by 2030 by registering a compound annual ...
HAPI: Why This Large-Cap Human Capital Factor ETF Works
HAPI ETF uses a proprietary method to select 150 U.S. large-cap companies with strong corporate cultures. Learn why I rate ...
Piramal Pharma Ltd: Piramal Pharma's GHG Commitment Validated and Approved by SBTi
Piramal Pharma has committed to reduce its GHG emissions for Scope 1, 2, and 3 by 2030MUMBAI, India, Sept. 16, 2024 ...